Endoscopic Resection for Small Rectal Neuroendocrine Tumors
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- The protocol lists: mEMR-C procedure, ESD procedure.
- Who it may be relevant to
- Registry conditions: Rectal Neuroendocrine Tumor. Basic parameters: 18 years — 75 years · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- Center list to be confirmed — check the primary protocol.
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Official title
Modified Cap-assisted Endoscopic Mucosal Resection and Endoscopic Submucosal Dissection for Small Rectal Neuroendocrine Tumors Less Than 1 cm: a Muticenter Randomized Noninferiority Trial
Overview
In previous single center study, both modified cap-assisted endoscopic mucosal resection (mEMR-C) and endoscopic submucosal dissection (ESD) were reported to be effective for the treatment of small rectal neuroendocrine tumors (NETs) and mEMR-C was inferior to ESD for the treatment of small rectal NETs (≤10 mm), as it has shorter operation times and lower hospitalization costs. However, a multicenter randomized controlled trial is needed to prove the universality and generality of these findings.
Detailed description
Investigators aimed to conduct a muticenter randomized controlled trial to compare mEMR-C with ESD for the treatment of small rectal neuroendocrine tumors (NETs) in six tertiary hospitals in China.
Interventions
- Procedure mEMR-C procedure
A transparent cap with an inner groove (MH-593; Olympus, Tokyo, Japan) was attached to the forward-viewing colonoscope. After the endoscope was inserted into the rectum, a crescent-shaped electrosurgical snare was passed through the sheath and looped along the inner groove of the cap. Submucosal injections were not required in this method. The tumor was suctioned into the cap and grasped by tightening the snare. After confirming the appropriate snare placement, both the tumor and overlying mucos - Procedure ESD procedure
ESD was performed as the standard procedure and has been widely described and used. First, dots were marked approximately 5 mm from the periphery of the lesion using coagulation. Subsequently, a diluted sodium hyaluronate solution with indigo carmine dye was injected submucosally. Mucosal incision and submucosal dissection were performed using a T-Type ESD Knife (Micro-Tech, Nanjing, China) or Dual-knife (Olympus Medical, Tokyo, Japan). After resection was completed, all visible vessels on the a
Primary outcome measures
- histological complete resection [Time frame: within 14 days after procedure]
Secondary outcome measures (8)
- success rate of operation [Time frame: intraoperative]
- en bloc resection [Time frame: intraoperative]
- operation time [Time frame: intraoperative]
- complications [Time frame: within 14 days after procedure]
- length of stay [Time frame: within 14 days after procedure]
- hospitalization cost [Time frame: within 14 days after procedure]
- operation cost [Time frame: within 14 days after procedure]
- histopathologic grade [Time frame: within 14 days after procedure]
Eligibility criteria
Inclusion criteria
- Age from 18 to 75 years;
- With a high suspicion or evidence of rectal NET assessed using EUS or colonoscopy;
- With tumor size ≤10 mm assessed by colonoscopy;
- Plan to receive mEMR-C or ESD treatment and provide written informed consent;
Exclusion criteria
- Unable to tolerate ESD or MEMR-C as assessed by the research team of each center;
- Complicated with serious diseases such as malignant tumor, which may lead to shorter life expectancy, the research team considers that it is not suitable for inclusion in the study after comprehensive evaluation;
- Rectal NET with lymph node metastasis or distant metastasis;
- Received resection of rectal neuroendocrine tumor by other surgical procedures;
- Multiple rectal neuroendocrine tumors;
- Vulnerable groups such as pregnant women or patients with mental disorders;
- Poor compliance, unable to cooperate with treatment.
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: No
Study design
- Allocation
- Randomized
- Model
- Parallel assignment
- Masking
- Open label
- Primary purpose
- Treatment
Study locations
Center list to be confirmed — check the primary protocol.
Identifiers
NCT: NCT05429216 · NFEC-2022-206